69 results about "Mucosal vaccine" patented technology

The invention discloses a fatty acid modified coronavirus antigen and application thereof, and belongs to the field of biological medicine. The fatty acid modified coronavirus antigen contains fatty acid modified N-terminal cysteine (Cys) and a coronavirus antigen, and can contain a connecting structural domain; the coronavirus antigen is a coronavirus spike protein (S protein) receptor binding domain (RBD). The fatty acid modified coronavirus S protein RBD can be self-polymerized into nanoparticles, and compared with the RBD which is not subjected to fatty acid modification, the antigen can induce faster and higher humoral immunity through injection immunity, can induce mucosal immunity and humoral immunity through respiratory tract atomization immunity, and is a candidate mucosal vaccine with potential medical value.

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

A recombinant multivalent vaccine including a recombinant protein is provided. The recombinant protein includes, from a N-terminus to a C-terminus, a first antigenic peptide, an N-polypeptide (SEQ ID NO: 1), a second antigenic peptide, a C-polypeptide (SEQ ID NO: 3) and a third antigenic peptide, where the N-polypeptide and the C-polypeptide are intramolecular scaffold-forming polypeptides, forming an intramolecular scaffold NC for supporting and stabilizing conformations of the first antigenic peptide, the second antigenic peptide and the third antigenic peptide. The recombinant multivalent vaccines 3Ro-NC (SEQ ID NO: 17) and 3Rs-NC (SEQ ID NO: 19) are provided to against SARS-COV-2 variants. The 3Ro-NC plus KFD is used as a prophylactic mucosal SARS-COV-2 vaccine to provide protection against Omicron infection in upper and lower respiratory tracts.

The invention provides a nano-selenium mucosal vaccine preparation, a preparation method, application and a vaccine. The nano-selenium mucosal vaccine preparation is specifically a nano-selenium mucosal vaccine preparation which is prepared by using chicken ovalbumin (OVA) as a protein antigen and modifying nano-selenium with polyethylene glycol (PEG). The invention aims to provide a nano-selenium mucosal vaccine preparation capable of overcoming mucosal barrier, successfully presenting antigen and inducing powerful immune response and a vaccine containing the preparation.

Hydration of a larynx and / or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and / or NaCl) can achieve prophylactic and / or therapeutic effects (e.g., cough suppression, improving voice quality, increasing pulse oxygen saturation and / or increasing mucosal vaccination effectiveness). The composition is administered as dry particles (e.g., aerosol) or as a liquid (e.g., solution, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 15 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5 mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.

A method of vaccinating a subject against a respiratory viral infection comprises concurrently or separately administering to a subject in need thereof one of more polynucleotide vector(s) encoding a respiratory virus antigen and one or more aerosolized respiratory virus antigen(s) to induce a mucosal immune response in the subject against an infection by respiratory viral infection. In another aspect, the present application provides a mucosal vaccine kit comprising one of more polynucleotide vector(s) encoding a respiratory virus antigen, one or more aerosolized respiratory virus antigen(s).

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

This invention discloses a method for rapidly constructing a complex of cholera toxin B subunit (CTB) and antigen. The vaccine complex includes a CTB-SpyTag fusion protein and at least one SpyCatcher-antigen fusion protein. It also includes a preparation method for rapidly preparing a CTB5-antigen complex by mixing CTB-SpyTag with the SpyCatcher-antigen. This invention directs the antigen to the side of the CTB pentamer that does not participate in GM1 binding, avoiding steric hindrance interference. It utilizes the SpyTag / SpyCatcher covalent isopeptide bond to obtain highly stable antigen display, reducing antigen shedding during subsequent preparation and storage. It also possesses mucosal targeting and multivalent presentation functions, providing a universal platform technology for rapidly constructing and validating broad-spectrum, combined, or personalized mucosal vaccines.

The present invention relates to novel peptides, compositions and uses thereof in tissue penetration, in particular in the context of cancer prevention and / or treatment or induction of an immune response, in particular mucosal vaccination or anti-opioid treatment.

The present invention relates to a vaccine composition for mucosal immunity and use thereof. It has been identified that the vaccine composition of the present invention is in the form of a 2D patch and effectively induces nasal mucosal immunity despite nasal mucociliary clearance (MCC). Thus, the vaccine composition provided in the present invention can be variously utilized for mucosal immunity in which various antigenic substances are used.

The invention provides a nano vaccine vector based on cholesteroid-free capsule protein and application of the nano vaccine vector, and belongs to the technical field of nano particle vaccines. The nano vaccine carrier is formed by sequentially connecting cholesteroid-free capsule protein, extension peptide, linker and molecular glue from an N end to a C end. The invention also provides a nano vaccine based on the cholesteric plasma-free capsule protein. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag, SpyTag002 or SpyTag003. The invention also provides a mycoplasma hyopneumoniae nano vaccine and a new crown nano vaccine. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag003. The nano vaccine vector disclosed by the invention can be used for intramuscular injection vaccines and mucosal vaccines for human and livestock, can remarkably improve the immune effect and enhance the immune response while displaying antigens, has a remarkable self-adjuvant effect, and provides a safe and efficient potential choice for the development of subunit vaccines.

Provided is an adjuvant for mucosal vaccines comprising a sulfated archaeosome comprising a sulfated glycoarchaeol. The glycoarchaeol may be present as a pharmaceutically acceptable salt. The adjuvant

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

The invention belongs to the technical field of medicines, and particularly relates to a vaccine preparation strategy taking new coronavirus spike protein as a respiratory mucosa vaccine antigen protein carrier, which is used for preventing respiratory pathogen infection. The novel coronavirus spike protein has good potential as a respiratory mucosa vaccine antigen vector, and can be used for enhancing mucosa and system immune response aiming at a target pathogen.

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

The invention provides recombinant lactobacillus plantarum for expressing porcine epidemic diarrhea virus S1 protein as well as a preparation method and application of the recombinant lactobacillus plantarum, and belongs to the technical field of preparation of porcine epidemic diarrhea virus vaccines. The recombinant lactobacillus plantarum provided by the invention contains a recombinant vector for expressing a PEDV tS1 fusion gene, and the PEDV tS1 fusion gene comprises a PEDV tS1 structural domain, an endogenous signal peptide 1320 and a dendritic cell targeting peptide DCpep. After the recombinant lactobacillus plantarum provided by the invention is used as a mucosal vaccine through nasal dripping, not only can a codon be prevented from being repeatedly optimized, but also strong cross-species immune response can be induced, pathogen specificity sIgA can be generated, mucosal immunity can be effectively activated, and the induced antibody has the activity of neutralizing PEDV (porcine epidemic diarrhea virus). The recombinant lactobacillus plantarum provided by the invention has a treatment effect.

To provide a compound that exhibits high migration ability to immune cells, enabling more efficient activation of the immune cells.SOLUTION: A compound has a plurality of first ligand moieties binding to C-type lectin receptors, a second ligand moiety binding to Toll-like receptors, and a linker with a branched structure where the first ligand moieties and the second ligand moiety are respectively bound at the terminals.SELECTED DRAWING: Figure 2

The invention relates to a SpaCBA-OVA liposome nanoparticle as well as a preparation method and application thereof. The SpaCBA-OVA liposome nanoparticle is formed by encapsulating SpaCBA and OVA in a liposome together, according to the SpaCBA-OVA lipidosome nanoparticles subjected to engineering modification, SpaCBA and OVA are jointly encapsulated in the lipidosome, so that continuous antigen release is given to encapsulated protein, and the limitation of mucosal vaccines is solved; through double receptor uptake, allergen presentation and immunomodulatory signal transduction are balanced, and the release of the dendritic cell immunomodulatory factor IL-10 / TGF-beta is enhanced, so that the problems proposed in the background technology can be well solved.

The application belongs to the technical field of biological medicine, and discloses a microneedle patch vaccine for inducing mucosal immune response and a preparation method and application thereof, specifically discloses a novel vaccine for inducing mucosal immune response, and the vaccine is delivered by a microneedle patch.The DNA nanoparticles wrapped by chitosan oligosaccharide are creatively combined with the microneedle technology, and it is proved that the strategy can induce a strong antigen-specific immune response in mucosal tissues such as lungs.The technology can be universally applied to the development of a novel mucosal vaccine for preventing mucosal route infectious pathogens (such as new coronavirus).

Among the various aspects of the present disclosure is the provision of a coronavirus vaccine and methods of making and using the same. The vaccine composition includes a nucleic acid encoding at least a portion of the genome of an adenovirus; and at least a portion of at least one phylogenetically inferred receptor binding domain (RBD) sequence from a Sarbecovirus clade or an immunogenic portion, variant, mutant, or fragment thereof.

This invention discloses a rice codon-optimized SARS-CoV-2 Omicron mutant receptor-binding domain dimer protein gene and its applications. The OdiRBD gene consists of two RBD sequences linked by a flexible peptide. Transgenic rice is pulverized and mixed with extraction buffer, then subjected to ultrasonic lysis followed by further extraction and filtration to obtain a crude extract containing OdiRBD. The crude extract containing OdiRBD is then subjected to nickel column chromatography to obtain purified OdiRBD. This method yields plants with stable expression, high extraction efficiency, and is suitable for large-scale production. The rice-derived OdiRBD purified by this method can effectively induce humoral, mucosal, and cellular immune responses in mice via intranasal immunization, and can be used for the development of rice-expressed mucosal vaccines, showing promising application prospects.

The present invention relates to the field of immunology, in particular, to mucosal vaccination. It provides a vaccine comprising a conjugate of an agent capable of specifically binding to an IgA or IgM, and an antigen. Said vaccine is advantageous for use in mucosal vaccination of a subject against said antigen, as it exploits an IgA feedback loop. The invention also provides methods for mucosal vaccination comprising administration of the vaccine of the invention to a subject. Furthermore, improved IgA binding peptides are disclosed.

The invention discloses a novel coronal virus mucosal immune vaccine based on a non-replicating vesicular stomatitis virus vector. The vaccine is delivered through a mucosal immunization way; the vaccine can be used in new crown vaccines, and can also be used in combination with other respiratory tract infection viruses such as respiratory syncytial vaccines (RSV) and influenza. At present, preparation of respiratory mucosa vaccines, especially multivalent vaccines, from replication-deficient VSV is not reported yet. According to the invention, safety and immunogenicity evaluation is carried out on the constructed VSVMT-S2P non-replicating recombinant VSV new crown vaccine in healthy narrative golden hamster and CP immunosuppression hamster models, and the VSVMT-S2P vaccine is found to be very safe in healthy animals; and the protein is highly safe in CP immunosuppressed hamsters. The VSVMT-S2P vaccine is subjected to single inoculation in the body of the narrative golden hamster through intranasal and intramuscular injection respectively, and it is proved that the VSVMT-S2P vaccine can effectively stimulate comprehensive immune response.

This invention relates to a mucosal vaccine composition and to an adjuvant comprising highly deacetylated chitosan for use in a method of immunotherapy, wherein the adjuvant is administered by a mucosal administration.

A non-infectious bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

The invention relates to the field of biological medicine, in particular to a nucleic acid delivery carrier compound formula and application thereof, and the nucleic acid delivery carrier compound formula is prepared from the following components in parts by mole: 5 to 12 parts of HEDMA-Apd-C12, 31.3 to 41.3 parts of D-lin-MC3-DMA, 10 to 28.8 parts of auxiliary phospholipid, 19.2 to 42.7 parts of cholesterol and 1.5 to 2 parts of PEG conjugated lipid. According to the formula, mRNA expressed by efficient protein can be wrapped and used for treating related defect diseases, and specific transfection is achieved in a T cell and NK cell system of a serum-free culture system. Compared with a DLin-MC3-DMA assembled cationic liposome formula and an SM-102 assembled cationic liposome formula, the effect of the formula disclosed by the invention is improved. The research provides a novel efficient and low-toxicity delivery strategy for cell and gene therapy, especially serum-free system CAR-T manufacturing, mucosal vaccine development and the like.

Embodiments of the present disclosure generally relate to compositions of a lyophilized (freeze dried) Listeria strain based therapeutics and a method for lyophilizing compositions of the therapeutics. A Listeria monocytogenes (LM) based vaccine formulation contains a lyophilized powder including a LM bacteria, the LM bacteria comprising at least one therapeutic agent and a lyophilization medium and a delivery composition. A method of forming a Listeria monocytogenes (LM) based vaccine formulation is disclosed. The LM based vaccine formulation includes resuspending an LM stock in a lyophilization medium to form a lyophilization composition, wherein the lyophilization medium comprises at least a lyoprotectant and a buffer component, freezing the lyophilization composition, lyophilizing the lyophilization composition, and forming a lyophilized powder, the lyophilized powder contains a LM bacteria, a lyoprotectant, and a buffer component.

The invention discloses a novel viable vaccine vector and application thereof. The invention relates to the technical field of biology, and provides recombinant shigella which is a strain obtained after a fim gene is introduced into receptor shigella. The fim gene is any one of the following: (A1) a DNA (Deoxyribose Nucleic Acid) molecule as shown in SEQ ID No.1; and (A2) a DNA molecule which has 80% or more of identity with the DNA sequence limited by (A1) and has the same function with the DNA sequence limited by (A1). The recombinant shigella provided by the invention is a carrier strain with shigella pili, can be used as a mucosal vaccine delivery carrier, and is used for researching oral viable bacteria carrier vaccines.

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); an influenza HA protein; and a trimerization domain. Disclosed are compositions comprising one or more of the peptides described herein. Disclosed are nucleic acid sequences capable of encoding any one of the peptides described herein. Disclosed are methods for eliciting a protective immune response against influenza comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; an influenza HA protein; and a trimerization domain, wherein the administering is to a mucosal epithelium. Disclosed are methods of treating a subject exposed to influenza or at risk of being exposed to influenza comprising administering to the subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; an influenza HA protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.